The effect of NeOpuntia® on blood lipid parameters - Risk factors for the metabolic syndrome (Syndrome X)

Advances in Therapy

Volumn 24, Issue 5, 2007, Pages 1115-1125

  Linarès, Elodie ^a   Thimonier, Catherine ^a   Degre, Michel ^a  

^a Parc Technologique du Lauragais   (France)

Author keywords

Cholesterol; Cladodes; HDL C; Metabolic syndrome; NeOpuntia ; Nopal; Opuntia ficus indica; Syndrome X

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEOPUNTIA; OPUNTIA EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LIPOPROTEIN; PLANT MEDICINAL PRODUCT;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; METABOLIC SYNDROME X; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; OPUNTIA; OUTCOME ASSESSMENT; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; AGE; BLOOD; MIDDLE AGED; PHYTOTHERAPY;

ADULT; AGE FACTORS; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; OPUNTIA; PHYTOTHERAPY; PLANT LEAVES; PLANT PREPARATIONS; TRIGLYCERIDES;

EID: 37348999665     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02877717     Document Type: Article

References (22)

1. Stintzing FC, Carle R. Cactus stems (Opuntia spp.): a review on their chemistry, technology, and uses. Mol Nutr Food Res. 2005;49:175-194.
2. Lozoya X. Tziuhpatli: Herba officinalis. Mexico City: SSA-UNAM; 1999.
3. Yarnell E, Abascal K, Hooper C. Clinical Botanical Medicine. New York: Mary Ann Liebert; 2003.
4. Wiese J, McPherson S, Odden MC, Shlipak MG. Effect of Opuntia ficus indica on symptoms of the alcohol hangover. Arch Intern Med. 2004;164:1334-1340.
5. Cardenas Medellin ML, Serna Saldivar SO, Velazco de la Garza J. Effect of raw and cooked nopal (Opuntia ficus indica) ingestion on growth and profile of total cholesterol, lipoproteins, and blood glucose in rats [in Spanish]. Arch Latinoam Nutr. 1998;48:316-323.
6. Galati EM, Tripodo MM, Trovato A, d'Aquino A, Monforte MT. Biological activity of Opuntia ficus indica Cladodes II: Effect on experimental hypercholesterolemia in rats. Pharm Biol. 2003;41:175-179.
7. Feugang JM, Konarski P, Zou D, Stintzing FC, Zou C. Nutritional and medicinal use of Cactus pear (Opuntia spp.) cladodes and fruits. Front Biosci. 2006;11:2574-2589.
8. International Diabetes Federation. The IDF concensus worldwide definition of the metabolic syndrome. Brussel: IDF 2005. http://www.idf.org/webdata/docs/ IDF_metasyndrome_definition.pdf.
9. Wolfram RM, Kritz H, Efthimiou Y, Stamotopoulos J, Sinzinger H. Effect of prickly pear (Opuntia robusta) on glucose- and lipid-metabolism in non-diabetics with hyperlipidemia - A pilot study. Wien Klin Wochenschr. 2002;114:840-846.
10. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986;74:1217-1225.
11. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease, four prospective American studies. Circulation. 1989;79:8-15.
12. Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol. 2006;21:345-352.
13. Meyers CD, Kashyap ML. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol. 2004;19:366-373.
14. Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab. 2007;32:46-60.
15. Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med. 2002;30-113(suppl 9B):13S-24S.
16. Aston LM. Glycaemic index and metabolic disease risk. Proc Nutr Soc. 2006;65:125-134.
17. LaRosa JC. Woman, lipoproteins and cardiovascular disease risk. Can J Cardiol. 1990;6B:23-29.
18. Ziai SA, Larjani B, Akhoondzadeh S, et al. Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabetic outpatients. J Ethnopharmacol. 2005;102:202-207.
19. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381-387.
20. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes. 2003;52:2346-2352.
21. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89:4963-4971.
22. Jaramillo-Flores ME, González-Cruz L, Cornejo-Mazón M, Dorantes-Alvarez L, Gutiérrez-López GF, Hernández- Sánchez H. Effect of thermal treatment on the antoxidant activity and content of carotenoids and phenolic compounds of cactus pear cladodes (Opuntia ficus-indica). Food Sci Technol Int. 2003;9:271-278.